The New England Journal of Statistics in Data Science logo


  • Help
Login Register

  1. Home
  2. To appear
  3. The Framework That Survives Bad Models: ...

The New England Journal of Statistics in Data Science

Submit your article Information Become a Peer-reviewer
  • Article info
  • Full article
  • Related articles
  • More
    Article info Full article Related articles

The Framework That Survives Bad Models: Human-AI Collaboration for Clinical Trials
Yao Chen 1   David Ohlssen 1   Aimee Readie 1     All authors (7)

Authors

 
Placeholder
https://doi.org/10.51387/26-NEJSDS111
Pub. online: 10 November 2026      Type: Case Study, Application, And/or Practice Article      Open accessOpen Access

1 Novartis Pharmaceuticals Corp., East Hanover, NJ.
2 Novartis Pharma AG, Basel, Switzerland.

Accepted
19 October 2025
Published
10 November 2026

Abstract

Artificial intelligence (AI) holds great promise for supporting clinical trials, from patient recruitment and endpoint assessment to treatment response prediction. However, deploying AI without safeguards poses significant risks, particularly when evaluating patient endpoints that directly impact trial conclusions. We compared two AI frameworks against human-only assessment for medical image-based disease evaluation, measuring cost, accuracy, robustness, and generalization ability. To stress-test these frameworks, we injected bad models—ranging from random guesses to naive predictions—to ensure that observed treatment effects remain valid even under severe model degradation. We evaluated the frameworks using two randomized controlled trials with endpoints derived from spinal X-ray images. Our findings indicate that using AI as a supporting reader (AI-SR) is the most suitable approach for clinical trials, as it meets all criteria across various model types, even with bad models. This method consistently provides reliable disease estimation, preserves clinical trial treatment effect estimates and conclusions, and retains these advantages when applied to different populations.

References

[1] 
Baeten, D., Sieper, J., Braun, J., Baraliakos, X., Dougados, M., Emery, P., Deodhar, A., Porter, B., Martin, R., Andersson, M., Mpofu, S. and Richards, H. B. (2015). Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. New England Journal of Medicine 373(26) 2534–2548. https://doi.org/10.1056/NEJMoa1505066. https://www.nejm.org/doi/pdf/10.1056/NEJMoa1505066.
[2] 
Chen, Y., Mo, Y., Readie, A., Ligozio, G., Mandal, I., Jabbar, F., Coroller, T. and Papież, B. W. (2024). VertXNet: an ensemble method for vertebral body segmentation and identification from cervical and lumbar spinal X-rays. Scientific Reports 14(1) 3341.
[3] 
Clark, K., Vendt, B., Smith, K., Freymann, J., Kirby, J., Koppel, P., Moore, S., Phillips, S., Maffitt, D., Pringle, M. (2013). The Cancer Imaging Archive (TCIA): maintaining and operating a public information repository. Journal of digital imaging 26 1045–1057.
[4] 
Deodhar, A., Blanco, R., Dokoupilová, E., Hall, S., Kameda, H., Kivitz, A. J., Poddubnyy, D., van de Sande, M., Wiksten, A. S., Porter, B. O. (2021). Improvement of signs and symptoms of nonradiographic axial spondyloarthritis in patients treated with secukinumab: primary results of a randomized, placebo-controlled phase III study. Arthritis & Rheumatology 73(1) 110–120.
[5] 
European Medicines Agency (2024). Reflection Paper on the Use of Artificial Intelligence in the Medicinal Product Lifecycle. EMA/CHMP/CVMP/83833/2023.
[6] 
Fournier, L., Costaridou, L., Bidaut, L., Michoux, N., Lecouvet, F. E., de Geus-Oei, L. -F., Boellaard, R., Oprea-Lager, D. E., Obuchowski, N. A., Caroli, A. (2021). Incorporating radiomics into clinical trials: expert consensus endorsed by the European Society of Radiology on considerations for data-driven compared to biologically driven quantitative biomarkers. European radiology 31 6001–6012.
[7] 
Guo, D., Yang, D., Zhang, H., Song, J., Zhang, R., Xu, R., Zhu, Q., Ma, S., Wang, P., Bi, X. et al. (2025). DeepSeek-R1: Incentivizing Reasoning Capability in LLMs via Reinforcement Learning. arXiv preprint arXiv:2501.12948.
[8] 
Harrer, S., Shah, P., Antony, B. and Hu, J. (2019). Artificial intelligence for clinical trial design. Trends in pharmacological sciences 40(8) 577–591.
[9] 
He, K., Zhang, X., Ren, S. and Sun, J. (2016). Deep residual learning for image recognition. In Proceedings of the IEEE conference on computer vision and pattern recognition 770–778.
[10] 
He, K., Gkioxari, G., Dollár, P. and Girshick, R. (2017). Mask r-cnn. In Proceedings of the IEEE international conference on computer vision 2961–2969.
[11] 
Isensee, F., Jaeger, P. F., Kohl, S. A., Petersen, J. and Maier-Hein, K. H. (2021). nnU-Net: a self-configuring method for deep learning-based biomedical image segmentation. Nature methods 18(2) 203–211.
[12] 
Mo, Y., Chen, Y., Readie, A., Ligozio, G., Coroller, T. and Papież, B. W. (2023). Towards automatic scoring of spinal X-ray for ankylosing spondylitis. arXiv preprint arXiv:2308.05123.
[13] 
Ng, A. Y., Glocker, B., Oberije, C., Fox, G., Sharma, N., James, J. J., Ambrózay, É., Nash, J., Karpati, E., Kerruish, S. (2023). Artificial intelligence as supporting reader in breast screening: a novel workflow to preserve quality and reduce workload. Journal of Breast Imaging 5(3) 267–276.
[14] 
Pai, S., Bontempi, D., Hadzic, I., Prudente, V., Sokač, M., Chaunzwa, T. L., Bernatz, S., Hosny, A., Mak, R. H., Birkbak, N. J. (2024). Foundation model for cancer imaging biomarkers. Nature machine intelligence 6(3) 354–367.
[15] 
Ronneberger, O., Fischer, P. and Brox, T. (2015). U-net: Convolutional networks for biomedical image segmentation. In Medical image computing and computer-assisted intervention–MICCAI 2015: 18th international conference, Munich, Germany, October 5-9, 2015, proceedings, part III 18 234–241. Springer.
[16] 
Taylor, H. G., Wardle, T., Beswick, E. J. and Dawes, P. T. (1991). The relationship of clinical and laboratory measurements to radiological change in ankylosing spondylitis. British Journal of Rheumatology 30(5) 330–335. https://doi.org/10.1093/rheumatology/30.5.330. https://academic.oup.com/rheumatology/article-pdf/30/5/330/5041584/30-5-330.pdf.
[17] 
Touvron, H., Lavril, T., Izacard, G., Martinet, X., Lachaux, M. -A., Lacroix, T., Rozière, B., Goyal, N., Hambro, E., Azhar, F. et al. (2023). Llama: Open and efficient foundation language models. arXiv preprint arXiv:2302.13971.
[18] 
U. S. Food and Drug Administration (2025). Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products: Draft Guidance for Industry. Draft guidance.
[19] 
U. S. Food and Drug Administration, Health Canada and Medicines and Healthcare products Regulatory Agency (2021). Good Machine Learning Practice for Medical Device Development: Guiding Principles.
[20] 
Van Der Heijde, D., Braun, J., Deodhar, A., Baraliakos, X., Landewé, R., Richards, H. B., Porter, B. and Readie, A. (2019). Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis. Rheumatology 58(3) 388–400.
[21] 
Vera, P. and Makhlouf, M. (2023). BIOptimus: Pre-training an Optimal Biomedical Language Model with Curriculum Learning for Named Entity Recognition. arXiv:2308.08625. https://arxiv.org/abs/2308.08625.
[22] 
Yang, Y., Yuan, Y., Zhang, G., Wang, H., Chen, Y. -C., Liu, Y., Tarolli, C. G., Crepeau, D., Bukartyk, J., Junna, M. R. (2022). Artificial intelligence-enabled detection and assessment of Parkinson’s disease using nocturnal breathing signals. Nature medicine 28(10) 2207–2215.
[23] 
Zhang, B., Zhang, L., Chen, Q., Jin, Z., Liu, S. and Zhang, S. (2023). Harnessing artificial intelligence to improve clinical trial design. Communications Medicine 3(1) 191.

Full article Related articles PDF XML
Full article Related articles PDF XML

Copyright
© 2026 New England Statistical Society
by logo by logo
Open access article under the CC BY license.

Keywords
AI Drug development Framework Bad models

Metrics
since December 2021
5

Article info
views

1

Full article
views

1

PDF
downloads

0

XML
downloads

Export citation

Copy and paste formatted citation
Placeholder

Download citation in file


Share


RSS

The New England Journal of Statistics in Data Science

  • ISSN: 2693-7166
  • Copyright © 2021 New England Statistical Society

About

  • About journal

For contributors

  • Submit
  • OA Policy
  • Become a Peer-reviewer
Powered by PubliMill  •  Privacy policy